<DOC>
	<DOCNO>NCT00526643</DOCNO>
	<brief_summary>The primary objective study evaluate impact overall survival ( OS ) addition cisplatin gemcitabine v gemcitabine alone patient advance NSCLC poor clinical condition ( PS 2 ) , previously treat .</brief_summary>
	<brief_title>CAPPA-2 : Cisplatin Added Gemcitabine Poor Performance Advanced NSCLC Patients</brief_title>
	<detailed_description>Performance status one important prognostic factor patient advance non-small cell lung cancer ( NSCLC ) , regardless treatment receive . Chemotherapy recommend advanced NSCLC patient good clinical condition , clear much benefit gain give chemotherapy patient poor general condition ( performance status 2 ) . This category patient represent 20 % patient initial diagnosis NSCLC , remain treatment challenge clinician . There study evaluate impact chemotherapy group patient , establish standard therapy . Studies evaluate single agent combination two-agent chemotherapy regimen ' impact survival improve symptom need .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance non small cell lung cancer , amenable surgical curative radiation therapy ( stage IIIB IV ) ; No prior concomitant chemotherapy ( adjuvant/neoadjuvant chemotherapy permit conclude least one year prior enrollment ) ; ECOG performance status 2 ; Age : &gt; = 18 &lt; 70 year ; Life expectancy least 4 week ; Normal bone marrow , hepatic renal function define : neutrophil &gt; = 2000/mm3 , PLT &gt; = 100,000/mm3 , Hb &gt; = 10.0 g/dl , Bilirubin &gt; = 1.5 time upper normal limit ( UNL ) , AST ALT &lt; = 3 time UNL ( 5 time presence liver metastasis ) , creatinine within normal limit ; Signed informed consent . Active systemic infection ; Severe concomitant illness ( congestive heart failure , angina pectoris , myocardial infarction within previous 6 month , cardiac arrhythmia treatment , severe arterial hypertension , severe uncontrolled diabetes mellitus ) ; Inadequate hepatic renal function ; Radiation therapy ongoing conclude within two week prior enrollment ; Symptomatic cerebral metastasis ; Previous chemotherapy advance disease ; Any condition would , investigator 's opinion , limit patient ability provide inform consent comply study procedure ; Pregnant nursing female ; Any malignancy within past 5 year ( except adequately treat carcinoma situ cervix non melanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage IIIB</keyword>
	<keyword>Stage IV</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>monotherapy</keyword>
	<keyword>combination chemotherapy</keyword>
	<keyword>poor performance status</keyword>
</DOC>